drugset

drugset / Trial / NCT03743129

Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）

NCT03743129 ↗

Phase 2 Completed 90 enrolled Anhui Shi, MD Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collab Peking University Cancer Hospital & Institute · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluate the efficacy and safety of Anlotinib following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer

Timeline

Start: 2019-04-12
Primary completion: 2021-11-11
Completion: 2021-11-11

Publications

Yang D, Li X, Xue X, Jiang L, Shi A, Zhao J. Anlotinib hydrochloride consolidation after concurrent chemoradiotherapy in stage III non-small-cell lung cancer: a truncated, randomized, multicenter, clinical study (ALTER-L029). Anticancer Drugs. 2024 Aug 1;35(7):680-685. doi: 10.1097/CAD.0000000000001617. Epub 2024 May 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	12 mg	—

Indications